Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial

The Lancet Oncology

Volumn 15, Issue 1, 2014, Pages 48-58

  O'Brien, Susan ^a   Furman, Richard R ^b   Coutre, Steven E ^c   Sharman, Jeff P ^d   Burger, Jan A ^a   Blum, Kristie A ^e   Grant, Barbara ^f   Richards, Donald A ^g   Coleman, Morton ^b   Wierda, William G ^a   Jones, Jeffrey A ^e   Zhao, Weiqiang ^e   Heerema, Nyla A ^e   Johnson, Amy J ^e   Izumi, Raquel ^h   Hamdy, Ahmed ^h   Chang, Betty Y ^h   Graef, Thorsten ^h   Clow, Fong ^h   Buggy, Joseph J ^h   James, Danelle F ^h   Byrd, John C ^e   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Willamette Valley Cancer Institute and Research Center US Oncology Research   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^g TEXAS ONCOLOGY   (United States)

^h PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IBRUTINIB;

ABDOMINAL PAIN; AGED; ANEMIA; ANXIETY; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; BACKACHE; CANCER GRADING; CANCER SURVIVAL; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; CONTUSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ACTIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY EYE; ENZYME INHIBITION; EPISTAXIS; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LYMPHOCYTOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL EDEMA; PETECHIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SENSORY NEUROPATHY; SINUSITIS; SMALL LYMPHOCYTIC LYMPHOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; VIRUS INFECTION; VOMITING;

EID: 84891373281     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70513-8     Document Type: Article

References (35)

1. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
2. Kenkre VP, Kahl BS The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep 2012, 7:216-220.
3. Wiestner A Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013, 31:128-130.
4. Gururajan M, Jennings CD, Bondada S Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006, 176:5715-5719.
5. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, Macewan DJ BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 2013, 25:106-112.
6. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010, 107:13075-13080.
7. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119:2590-2594.
8. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119:1182-1189.
9. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
10. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31:88-94.
11. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
12. Gribben JG, O'Brien S Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011, 29:544-550.
13. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49-53.
14. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
15. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006, 24:437-443.
16. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
17. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230-239.
18. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382-3391.
19. Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013, 31:440-447.
20. Goede V, Fischer K, Busch R, et al. Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in. Leukemia 2013, 27:1172-1174.
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
22. Jaffe ES, Harris NL, Stein H, Isaacson PG Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008, 112:4384-4399.
23. Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes. Blood 2012, eUpdate June 4, 2012., (accessed Oct 11, 2013). http://bloodjournal.hematologylibrary.org/content/111/12/5446.full/reply#bloodjournal_el_6920.
24. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012, 30:2820-2822.
25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
26. Claus R, Lucas DM, Stilgenbauer S, et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 2012, 30:2483-2491.
27. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
28. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
29. Goede V, Fischer K, Humphrey K, et al. Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab versus Clb alone in patients with chronic lymphocytic leukemia and preexisting medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) phase III trial. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 7004.
30. Goede V, Fischer K, Kreuzer K-A, et al. Kinetics of blood cell subpopulations during treatment with obinutuzumab (GA101) + chlorambucil (GClb), rituximab +Clb (RClb) versus Clb alone in patients with chronic lymphocytic leukemia and coexisting medical conditions: stage I results of the CLL11 (BO21004) trial. Biennial International Workshop on CLL (iwCLL) 2013; Sept 9-11, 2013; Cologne, Germany: abstr 4.14.
31. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
32. Burger JA, Keating MJ, Wierda WG, et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Blood 2012, 120:187.
33. Ferrajoli A, O'Brien S, Wierda WG, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma 2005, 46:S87.
34. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
35. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122:2539-2549.